Sign in
CompletedPhase 1/2

Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study

Key facts

Who runs it
Murdoch Childrens Research Institute
Where
Australia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
10 people enrolled
Started
16 May 2022
Ended
4 Jan 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.
  • Placebo
Record updated
27 November 2024

Who can take part

Age
12 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Males and females aged 12 - 18 years of age
  • DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) diagnosis of TS as assessed by the study clinician
  • TS severity defined as a score of 20 or higher on the Total Tic Severity section of the Yale Global Tic Severity Scale
  • No changes in either medication or other interventions in the 4 weeks prior to randomization, and intention to remain on same dose for the duration of the study
  • Participant and family have the ability to comply with the protocol requirements, in the opinion of the investigator
  • Agrees not to drive for the duration of the study

Who cannot take part

  • Current use of illicit drugs or medicinal cannabis, or use in the 4 weeks prior to screening
  • History of clinically significant suicidal thoughts in the prior 12 months
  • Participant history of psychosis, schizophrenia, bipolar disorder, or major depressive disorder, or a family history of psychosis
  • Taking anti-epileptic medications which interact with medicinal cannabis: clobazam, mTOR (mammalian target of rapamycin) inhibitors (e.g sirolimus, tacrolimus), anti-cancer agents, citalopram >20mg/day, escitalopram >10mg/day
  • Abnormal liver function tests defined as ALT (alanine transaminase) > twice ULN (upper limit of normal)
  • Non-English speaking parents
  • Pregnant or intending to become pregnant during the study, or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single site, pilot double-blind, randomized, placebo-controlled, cross-over study of 10 participants comparing medicinal cannabis (THC:CBD 10:15 oil) with placebo in reducing tics in adolescents aged 12 - 18 years with severe Tourette Syndrome (TS).

Read full original descriptionShow less

The primary objective of this pilot study is to evaluate all elements of the study design (recruitment strategy, study duration, study procedures, study medication tolerance and outcome measures) to assess if they are acceptable and feasible for the conduct of a full-scale randomized controlled trial of THC:CBD 10:15 oil to reduce tic severity in adolescents with TS.

The secondary objective of this study is to collect preliminary data on the safety of oral THC:CBD 10:15 oil in adolescents aged 12 to 18 years with TS.

As an exploratory aim data from clinician- and parent-rated measures will be compared across the phases to explore for a signal of efficacy on primary (tic reduction) and secondary (premonitory urges, obsessive compulsive behaviors, Attention Deficit Hyperactivity Disorder [ADHD] symptoms) outcome measures.

The 2 groups in the trial

  • Group A (MC then placebo)Treatment being tested

    Group A will receive medicinal cannabis during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive placebo during Treatment Period 2 (70 days).

    Treatment: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd. and Placebo

  • Group B (placebo then MC)Treatment being tested

    Group B will receive placebo during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive medicinal cannabis during Treatment Period 2 (70 days).

    Treatment: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd. and Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Randomized Placebo-controlled Crossover Trial of Medicinal Cannabis (MC) in Adolescents with Tourette Syndrome (TS)
Publications
Record updated
27 November 2024